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Abstract
Background: Interferon-gamma release assays have emerged as a more specific alternative to the tuberculin skin
test (TST) for detection of tuberculosis (TB) infection, especially in Bacille Calmette-Guérin (BCG) vaccinated people.
We determined the prevalence of Mycobacterium tuberculosis infection by TST and QuantiFERON®-TB Gold In-Tube
(QFT-GIT) and assessed agreement between the two test methods and factors associated with positivity in either
test in Warao Amerindian children in Venezuela. Furthermore, progression to active TB disease was evaluated for up
to 12 months.
Methods: 163 HIV-negative childhood household contacts under 16 years of age were enrolled for TST, QFT-GIT
and chest X-ray (CXR). Follow-up was performed at six and 12 months. Factors associated with TST and QFT-GIT
positivity were studied using generalized estimation equations logistic regression models.
Results: At baseline, the proportion of TST positive children was similar to the proportion of children with a positive
QFT-GIT (47% vs. 42%, p = 0.12). Overall concordance between QFT-GIT and TST was substantial (kappa 0.76, 95% CI
0.46-1.06). Previous BCG vaccination was not associated with significantly increased positivity in either test (OR 0.68,
95% CI 0.32-1.5 for TST and OR 0.51, 95% CI 0.14-1.9 for QFT-GIT). Eleven children were diagnosed with active TB at
baseline. QFT-GIT had a higher sensitivity for active TB (88%, 95% CI 47-98%) than TST (55%, 95% CI 24-83%) while
specificities were similar (respectively 58% and 55%). Five initially asymptomatic childhood contacts progressed to
active TB disease during follow-up.
Conclusion: Replacement of TST by the QFT-GIT for detection of M. tuberculosis infection is not recommended in this
resource-constrained setting as test results showed substantial concordance and TST positivity was not affected by
previous BCG vaccination. The QFT-GIT had a higher sensitivity than the TST for the detection of TB disease. However, the
value of the QFT-GIT as an adjunct in diagnosing TB disease is limited by a high variability in QFT-GIT results over time.
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Background
Tuberculosis (TB) in children is an important public
health problem. Worldwide, at least half a million children
become ill with TB and as many as 70,000 children die of
TB each year [1]. A unique aspect of TB in young children
is the rapid progression to disease, typically within the first
year following infection, unlike in adults, where latent TB
infection (LTBI) can persist for decades without progres-
sion into active disease [2]. The tuberculin skin test (TST)
is a simple and relatively cheap test for the detection of
LTBI. However, the specificity of the TST is affected by
cross-reactivity with the Bacille Calmette-Guérin (BCG)
vaccine and exposure to nontuberculous mycobacteria [3].
Interferon-gamma release assays (IGRAs) have emerged
as a more specific alternative to the TST [4].
A systematic review of studies comparing IGRAs and
TST in children concluded that the tests have similar
accuracy for the detection of LTBI or active TB [5].
However, a meta-analysis of QuantiFERON®-TB Gold In-
Tube (QFT-GIT) sensitivity in children and adults in
high burden vs. low burden TB settings showed a clear
trend towards lower QFT-GIT sensitivity in high burden
settings [6].
In several adult studies, a relationship between CXR or
chest computed tomography (CT) lesions indicative of pre-
vious TB and TST or IGRA positivity has been observed
[7-10]. The observation that rates of IGRA positivity are
higher in individuals with CXR and CT lesions suggesting
old healed TB than in those without such lesions [8] is in
contrast with the suggestion that IGRA results become
negative once the mycobacteria enter a dormant state [11].
Studies performing serial IGRA testing in childhood
household contacts are scarce and suggest that both con-
versions and reversions of IGRA results occur [12-14].
None of these studies assessed the relationship between
IGRA or TST results and CXR lesions suggestive of previ-
ous TB.
Although IGRAs are more costly and technically com-
plex than the TST, they offer the advantage of requiring
only a single patient visit whereas the TST requires a
health care professional reading the induration size at 48
to 72 hours. Published reports regarding return rates for
TST assessment vary widely from 12% to 72% [15-19].
Low return rates are especially worrisome when the TST
is used as an adjunct in diagnosing TB disease, since this
can lead to under-diagnosis of TB if children that do not
show up for a return visit remain undiagnosed.
In Venezuela, the national prevalence of TB is moderate
(25–87 per 100,000 inhabitants) [20], but an extraordinarily
high TB prevalence (3190 per 100,000) has been reported
in Warao Amerindian children [21]. This indigenous popu-
lation resides in the Orinoco River Delta, where they live
in wooden houses raised on stilts along the Orinoco River
banks. Tuberculin purified protein derivative used for TST
testing is not widely available in the Warao communities,
although surveys using TST testing have been performed
[22]. The diagnosis of TB disease and the subsequent initi-
ation of TB treatment occurs through the Orinoco Delta
Department of the Venezuelan National TB Program situ-
ated in the hospital in Tucupita, the state capital city of the
Orinoco Delta on the mainland. When an individual is di-
agnosed in this hospital, TB treatment is transported to the
community in which the patient lives, where it is given to
community nurses that are responsible for the delivery and
supervision of TB treatment. Isoniazid preventive therapy
is currently not routinely provided for childhood contacts
of adult TB patients in the Orinoco Delta. While some
Warao people have family members who live in Tucupita,
many do not which means that they do not have a place to
stay when visiting Tucupita to go the hospital. As a conse-
quence, many Warao people prefer to return to their com-
munities the same day rather than staying in Tucupita for
the night. This leads to under-diagnosis and subsequent
under-treatment of TB when TST results are awaited in
order to make a definite TB diagnosis. The IGRA could po-
tentially decrease the under-diagnosis related to failure to
adhere to return visits in this specific setting.
The primary objectives of our study were 1) to determine
the prevalence of Mycobacterium tuberculosis infection by
TST and QFT-GIT and assess agreement between the two
test methods and 2) to identify characteristics associated
with TST positivity and QFT-GIT positivity in childhood
TB contacts. Secondary objectives were the assessment of
the QFT-GIT and TST performance to detect TB disease
and predict the development of TB disease and their rela-
tionship with radiological features possibly indicating the
presence of TB sequelae.
Methods
Study design and setting
Warao Amerindian children under 16 years of age residing
in the municipalities Antonio Díaz and Pedernales in the
Orinoco Delta in Northeastern Venezuela who were
household contacts of culture-confirmed TB patients who
registered for TB treatment in the Venezuelan National
TB Control Program were included between May 2010
and December 2011. All included household contacts
underwent QFT-GIT testing, TST and CXR examinations.
A previously published cross-sectional analysis reported
on the association of TST and QFT-GIT positivity with
helminth infections and cytokine profiles in asymptomatic
Warao childhood TB household contacts [23]. For the
prospective study presented here, all childhood contacts of
culture-confirmed TB patients, both symptomatic and
asymptomatic, from 0–15 years of age who were identified
within six months after registration of the index case
between May 2010 and December 2011 were included, if
they did not meet the exclusion criteria. Exclusion criteria
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were absence of a written informed consent, untracibility
of the registered index patients and their contacts for in-
clusion, a positive Human Immunodeficiency Virus (HIV)
test at any time point, TST administration in the three
months before inclusion, laboratory documented anemia
(hemoglobin <9 g/dl) at inclusion and previous TB
treatment.
At six-month follow-up, CXR and QFT-GIT were
taken of children that were diagnosed with TB and put
on TB treatment at inclusion. In addition, active follow-
up was performed in order to screen for children that
did not have active TB at inclusion but developed active
TB within the first six months after inclusion. To this
end, a TST and physical examination were performed in
all encountered children. Subsequently, those children
that converted from TST negative to TST positive as
well as those children presenting any sign or symptom
that may be associated with active TB (ie, any of reported
or documented fever, cough, weight loss or failure to
thrive, lethargy or decrease in playfulness/activity or en-
larged lymph nodes or auscultatory findings that may indi-
cate airway disease) underwent CXR and QFT-GIT.
At 12-month follow-up, all included children were
followed up with CXR and QFT-GIT, irrespective of
TST or physical examination results. Repeat TST testing
during follow-up was only performed in children that
were previously TST negative. In addition to the active
follow-up at six and 12 months, the cohort was monitored
by passive follow-up with a focus on TB development
based on reports to the Orinoco Delta Department of the
National TB Control Program. Furthermore, four of the
authors (LMV, MM, LPR and JAV) resided in the Orinoco
Delta at the time of research where they periodically
visited communities in the study region.
Sample collection
Blood was collected for QFT-GIT assays [24] and Human
Immunodeficiency Virus (HIV) antibody testing using the
Determine™ (Abbot Laboratories, Illinois, USA) HIV 1/2
rapid test. The tubes for the QFT-GIT assay were incu-
bated on site with a portable incubator. HIV testing was
performed upon inclusion and at 12-month follow-up in
all children. The TST was performed using 0.1 mL of
tuberculin purified protein derivative (PPD RT23, Statens
Seruminstitut, Copenhagen, Denmark). Reading was per-
formed by trained professionals measuring the palpable
transverse induration on the volar surface of the forearm
between 48 and 72 hours after administration. Antero-
posterior and lateral CXRs were taken. Two independent
experts, blinded to all clinical information except for age,
evaluated the CXRs. Where the two experts disagreed, a
third expert was consulted and final consensus was
achieved. A sputum sample was collected from all chil-
dren who could expectorate with gastric aspirates taken
from all children under 6 years of age upon inclusion.
During follow-up, sputum or gastric aspirate samples were
only taken from symptomatic children. Specimens were
cultured on Middlebrook (7H9) liquid broth-based media
and on Ogawa solid media.
Definitions
Confirmed TB was defined as isolation of M. tuberculosis
on culture. PCR-restriction analysis of the hsp65 gene
(PRA) was performed to differentiate M. tuberculosis from
nontuberculous mycobacteria. Probable TB was defined as
clinical signs and symptoms of TB and radiographic find-
ings consistent with intrathoracic TB as defined by Marais
et al. [25], and either (1) a positive TST or QFT-GIT or
(2) histopathologic findings compatible with TB, without
positive mycobacterial culture results. Possible TB was de-
fined as clinical signs and symptoms of TB and abnormal
CXR findings not consistent with but possibly related to
active TB (eg, nonspecific shadows) and either (1) or (2).
In children <3 years of age, a diagnosis of probable or pos-
sible TB was also made when clinical signs and symptoms
of TB were present together with radiographic findings
but without a positive TST or QFT-GIT, because in this
age group these T-cell based tests have low sensitivity for
TB disease [26]. When clinically indicated, additional
examinations to diagnose extrapulmonary forms of TB
were performed.
CXRs were classified as (1) normal (no abnormalities
suggestive of current or past TB observed), (2) active TB
or (3) radiographic lesions possibly related to past pul-
monary TB (TB sequelae). The latter category was defined
as the presence of at least one of the three radiological fea-
tures (calcification, parenchymal destruction with fibrosis,
bronchiectasis) defined as ‘consequences of previous pul-
monary tuberculosis’ by Marais et al. [25]. CXR findings
regarded as compatible with bronchiectasis were saccular
changes or cylindrical outlines of airways that widened as
airways extended into the lung periphery [27,28].
Previous BCG vaccination was defined as the presence
of a BCG scar. Height and weight were recorded and
transformed into weight-for-height, height-for-age, and
body mass index (BMI)-for-age Z scores based on WHO
standard reference populations [29,30] using WHO
anthro software [31]. Children under 5 years of age with
weight-for-height or height-for-age Z scores <−2 standard
deviations (SD) were defined as malnourished. Children
aged 5 to 15 years with BMI-for-age or height-for-age Z
scores <−2 SD were defined as malnourished [32-34].
Venezuelan National TB Program guidelines regard a
TST ≥10 mm 48–72 hours after injection as positive. A
TST conversion was defined as having a negative TST at
baseline and a TST ≥10 mm at any follow-up time point.
An induration of <10 mm was considered TST negative.
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A positive QFT-GIT was defined as a TB antigen minus
nil (negative control) value ≥0.35 IU/ml and ≥25% of nil
value. A nil value of >8.0 IU/ml or a mitogen minus nil
of <0.5 IU/ml was classified as indeterminate. QFT-GIT
conversion or reversion was defined as respectively a nega-
tive to positive or a positive to negative change according to
manufacturer’s criteria (ie, baseline IFN-γ <0.35 IU/ml and
follow-up IFN-γ ≥0.35 IU/ml or baseline IFN-γ ≥0.35 IU/
ml and follow-up IFN-γ <0.35 IU/ml respectively) [24].
Ethical considerations
The nature and objectives of the study were explained to
the parents of exposed children in Spanish and/or in their
native language. The study was approved by the ethical
committee of the Instituto de Biomedicina, the Regional
Health Services, and the Delta Amacuro Indigenous
Health Office (Servicio de Atención y Orientación al Indí-
gena). Children were enrolled if their parents or primary
caregivers provided written informed consent. If parents
or primary caregivers were illiterate, consent forms were
read to them in Spanish and/or in their native language by
Spanish-Warao bilingual native interpreters and signed by
means of a thumb print.
Children diagnosed with confirmed, probable or pos-
sible TB were treated with a standard six month anti-TB
regime as recommended by the Venezuelan National TB
Control Program.
Sensitivity, specificity, positive and negative predictive
value calculations
The sensitivity and specificity of the TST and QFT-GIT
for active TB were calculated. For these estimations, chil-
dren that died from an unknown cause as well as children
diagnosed with TB at six or 12 month follow-up were ex-
cluded. Additionally, the positive and negative predictive
values of TST and QFT-GIT testing for the identification
of initially asymptomatic children that progressed to active
TB and would thus have benefited from preventive treat-
ment were calculated.
Statistical analysis
Test concordance was calculated using the Kappa (ĸ) coef-
ficient statistic. Categorical unpaired and paired data were
compared using respectively Chi-square (or Fisher’s exact
test, as appropriate) and McNemar’s tests. For unpaired
continuous variables, the unpaired Student’s t test or the
nonparametric Mann-Whitney’s test was used depending
on whether or not the variables were normally distributed
(Kolmogorov-Smirnov’s test, p > 0.05).
Generalized estimation equations (GEEs) were used to fit
multivariable logistic regression models aimed at identify-
ing possible associations between QFT-GIT or TST posi-
tivity (dependent variable) and BCG vaccination, age, sex,
malnourishment and duration of exposure (independent
variables) and between the presence of possible TB seque-
lae on CXR (dependent variable) and IFN-γ level, TST
induration, BCG vaccination, age, sex, malnourishment
and duration of exposure (independent variables). GEEs
account for correlation and lack of independence of
responses for contacts with an index TB case in common
(clusters within households). Results were reported as
adjusted odds ratios (OR) with 95% confidence intervals
(CI). SPSS software for windows, version 20.0 (SPSS Inc,
Chicago, IL, USA) was used for statistical analyses. Statis-
tical significance was set to p-value <0.05.
Results
At baseline 163 household contacts were enrolled for TST
testing, QFT-GIT and CXR (Figure 1). Six registered adult
TB patients were untraceable and in one household, par-
ents were not willing to enroll their children in the study.
For 149 children (91%), results for TST and QFT-GIT as
well as CXR were available (Figure 2). The mean age of in-
cluded children was 7.7 years (standard deviation 4.2 years).
Additional data at inclusion, classified by age group, are
summarized in Table 1.
Of the 163 children, 11 (7%, 95% CI 3-12%) were diag-
nosed with active TB at baseline. In the children with both
a TST and a QFT-GIT result available, the proportion of
children with a positive TST was somewhat but not signifi-
cantly higher than the proportion of children with a posi-
tive QFT-GIT (47% vs. 42%, p = 0.12). When excluding
indeterminate results, the concordance between TST and
QFT-GIT was substantial (ĸ 0.76, 95% CI 0.46-1.06,
Table 2). The concordance between TST and QFT-GIT
was lower but still substantial in BCG vaccinated children
compared with children who were not BCG vaccinated
(ĸ 0.74, 95% CI 0.62-0.86 vs. ĸ 0.89, 95% CI 0.68-1.09 re-
spectively). Previous BCG vaccination, malnourishment
and duration of exposure were not significantly associated
with either TST or QFT-GIT positivity in multivariable
analysis (Table 3). TST positivity rates were higher in males
compared with females (OR 3.7, 95% CI 1.5-9.4) and in-
creased with each year of age (OR 1.4, 95% CI 1.2-1.7).
QFT-GIT positivity was not significantly associated with
these factors in multivariable analysis (Table 3).
TST and QFT-GIT results in children with active TB at
inclusion
At inclusion, 11 children were diagnosed with active TB,
of which two were confirmed pulmonary TB, four were
probable and four were possible intrathoracic TB. One
child was diagnosed with intrathoracic and hip bone TB.
Five children were TST negative and six had a positive
TST result, corresponding to 55% sensitivity (95% CI
24-83%) and 55% specificity (95% CI 47-64%) of the TST
for active TB. The QFT-GIT was not performed in two
children with active TB due to logistical difficulties.
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Excluding these children as well as the children with an
indeterminate QFT-GIT result, the QFT-GIT had a 88%
sensitivity (95% CI 47-98%) and 58% specificity (95% CI
49-67%) for the diagnosis of active TB. However, the
small sample size and the low number of children with
active TB as well as the fact that TST or QFT-GIT posi-
tivity was one of the criteria for the diagnosis of active
TB preclude firm conclusions regarding the value of
QFT-GIT and TST testing for the diagnosis of active TB
in this population.
Progression to active TB during follow-up
At six-month follow-up, 105 children were clinically ex-
amined: 7 children that were diagnosed with TB at inclu-
sion and 98 children that were asymptomatic at inclusion
(Figure 1). Follow-up examinations confirmed a diagnosis
of possible or probable TB in four of these 98 children
(4%). At 12-month follow-up, 64 initially asymptomatic
children were encountered (Figure 1) and TB was diag-
nosed in one additional boy that did not present with TB
disease at inclusion or six-month follow-up. The mean
age of the five children that developed active pulmonary
TB during follow-up was lower than the mean age of all
included children (respectively 4 vs. 8 years). Demographic
characteristics and test results of these children are sum-
marized in Table 4. None of these five children converted
from either TST negative to positive or from QFT-GIT
negative to positive. Three of the five children were TST
positive at inclusion and two also had a positive QFT-GIT
result (Table 4, Figure 2). To estimate the value of TST
and QFT-GIT testing for the identification of these
children that would benefit from preventive treatment, we
calculated their positive and negative predictive values. Of
the 76 initially asymptomatic QFT-GIT negative contacts,
two developed active TB, yielding a negative predictive
value of 97% (95% CI 91-100%). Of the 84 initially asymp-
tomatic TST negative children, two developed TB, result-
ing in a negative predictive value of 98% (95% CI 92-
100%). Positive predictive values were much lower, 4%
(95% CI 1-12%) and 3% (95% CI 0-10%) for QFT-GIT and
TST respectively.
TST and QFT-GIT results during follow-up
At inclusion, 89 children were TST negative (Table 2). In
60 (67%) of these initially TST negative children, a repeat
TST was performed during follow-up. There were no dif-
ferences in the age or sex characteristics of those initially
TST negative contacts in which a repeat TST was per-
formed vs. those without a follow-up TST. Nine children
(15% of all children with a repeat TST result) converted
from TST negative to TST positive during follow-up.
QFT-GIT results at both inclusion and 12 month
follow-up were available for 57 children. There was no sig-
nificant age difference between these children and the
(163–57) 106 children for whom QFT-GIT results at both
time points were not available. Girls were more likely to
have follow-up QFT-GIT results than boys (44% vs. 28%,
p = 0.041). One third of the 57 children with both results
available (n = 19) had a QFT-GIT result at 12-month
follow-up that was not identical to their result at inclusion
(Additional file 1: Table S1). There were no significant dif-
ferences in the age and sex characteristics of children that
Refused n = 2
Died n = 1
Not encountered n = 1
Refused n = 9
Died n = 0
Not encountered n = 45
Refused n = 11
Died n = 1
Not encountered n = 76
Active TB
n = 11
TST: n = 11 (100%)
QFT-GIT: n = 9 (82%)
CXR: n = 11 (100%)
No active TB
n = 152
TST: n = 152 (100%)
QFT-GIT: n = 142 (93%)
CXR: n = 148 (97%)
Six-month follow-up
Physical examination: n = 7 (64%)
QFT-GIT: n = 7 (64%)
CXR: n = 7 (64%)
Refused n = 2
Died n = 2
Not encountered n = 2
12-month follow-up
QFT-GIT: n = 5 (45%)
CXR: n = 5 (45%)
Six-month follow-up
Physical examination: n = 98 (64%)
Diagnosed with TB disease: n = 4
Conversion to TST-positive: n = 5
12-month follow-up
Physical examination: n = 64 (42%)
Diagnosed with TB disease: n = 1
Conversion to TST-positive: n = 4
QFT-GIT: n = 58 (38%)
CXR: n = 60 (39%)
Figure 1 Study recruitment profile and number of children assessed at different time points.
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changed their QFT-GIT result compared with those in
which the follow-up QFT-GIT result was identical to the
recruitment result. Of the initially QFT-GIT positive chil-
dren with valid follow-up data, 62% reverted to negative
or indeterminate while only 15% of the initially QFT-GIT
negative children showed a different result at 12-month
follow-up (p < 0.01, Additional file 1: Table S1). Median
quantitative recruitment QFT-GIT responses in QFT-GIT
positive contacts that reverted to negative were lower than
responses in those QFT-GIT positive contacts that
remained positive (1.3 IU/ml, range 0.85-8.8 vs. 3.7 IU/ml,
range 1.2-5.3). Similarly, median quantitative recruitment
responses in children that converted from QFT-GIT
negative to positive were somewhat higher than responses
in those QFT-GIT negative contacts that remained nega-
tive (0.021 IU/ml, range −0.001 to 0.32 vs. 0.002 IU/ml,
range −7.6 to 0.17).
Chest X-ray findings in children without active TB
In 61/148 (41%) children without active TB and valid
CXR results at inclusion at least one radiographic fea-
ture of possible TB sequelae was detected. Most children
(n = 46, 31%) showed calcifications (Table 5). In 39
(85%) of the children with calcifications, this was the
sole abnormality detected. A total number of 17 children
(11%) showed radiological features suggestive of bron-
chiectasis (Table 5) and in 11 of them (65%) this was the
sole abnormality detected.
Of the 148 children, 57 (39%) had a repeat CXR at 12-
month follow-up. Of the 57 children with valid CXR
results at both inclusion and 12-month follow-up, six
(11%) showed TB sequelae at the follow-up CXR while
these were not present at the CXR taken upon inclusion.
All six children showed calcifications (bilateral in four
children and segmental in two children); no child showed
parenchymal destruction or bronchiectasis at 12 month
follow-up that was not present upon inclusion. Five of the
six children were QFT-GIT negative at inclusion; in one
child no QFT-GIT was performed. At 12 month follow-
up, the appearance of calcifications was not accompanied
by a reversion of the QFT-GIT results in these five children;
all QFT-GIT levels remained around 0. In one child the ap-
pearance of segmental calcifications on CXR was accom-
panied by a conversion from TST negative (0 mm) to TST
positive (13 mm) while the QFT-GIT level did not change
(respectively −0.031 and 0.007 IU/ml).
When the presence of possible TB sequelae on CXR was
taken as a dependent variable in multivariable logistical
GEE regression analysis, four independent factors were
found to be significantly associated: IFN-γ level in IU/ml,
Figure 2 QuantiFERON®-TB Gold in-tube assay (QFT-GIT) and
tuberculin skin test (TST) data upon inclusion from the 149
included children with both results and chest X-rays (CXRs)
available. The QFT response is the level of IFN-γ (IU/ml) in the
tuberculosis (TB) antigen-stimulated plasma sample with that for the
negative control subtracted. Results for those 9 children who were
diagnosed with TB at inclusion are represented by solid diamonds
(in 2 children diagnosed with TB no QFT-GIT was performed). Results
for those who showed TB sequelae at CXR are represented by asterisks.
The arrows point to the results of 4/5 children (in 1 child no QFT-GIT
was performed at inclusion) who progressed to active TB during
follow-up. The dotted line represents the 0.35 IU/ml cutoff for the
QFT-GIT test.
Table 1 Characteristics of study population classified by
age group
Characteristics,
n (%)
0-5 years 6-10 years 11-15 years
n = 54 (33%) n = 62 (38%) n = 47 (29%)
Male 29 (54) 38 (61) 25 (53)
Female 25 (46) 24 (39) 22 (47)
TST positive 6 (11) 32 (52) 36 (77)
Active TB disease 2 (4) 5 (8) 4 (9)
Malnourished 31 (57) 20 (32) 13 (28)
BCG vaccinated 41 (76) 58 (94) 41 (87)
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age, sex and BCG vaccination status (Table 6). Every unit
increase of IFN-γ per milliliter was marginally significantly
associated with an increased risk of having TB sequelae
(p = 0.049). Furthermore, the risk of having TB sequelae
increased significantly with each year of age (OR 1.3, 95%
CI 1.0-1.6, p = 0.029), was higher in boys than in girls (OR
1.8, 95% CI 1.1-3.0) and in BCG vaccinated children com-
pared with unvaccinated children (OR 2.7, 95% CI 1.2-
6.5). Additionally, there was a trend towards a lower risk
of having TB sequelae on CXR in malnourished children
(p = 0.055) in multivariable analysis. TST induration diam-
eter was not found to be associated with the presence of
possible TB sequelae (p = 0.44, Table 6).
Discussion
To our knowledge, this study is the first to investigate the
relative utility of QFT-GIT and TST in South American
indigenous children. A substantial concordance between
TST and QFT-GIT results was observed and BCG vaccin-
ation was not associated with significantly increased posi-
tivity in either test. Both tests had a high negative
predictive value (≥97%) but a low positive predictive value
(≤4%) for the identification of contacts that developed ac-
tive TB disease over time. Two earlier prospective studies
including child TB contacts in Japan [35] and Germany
[36] also reported high negative predictive values and low
positive predictive values of QFT assays for progression to
active TB disease. However, the proportion of children
that were lost to follow-up in our study was very high
(Figure 1) compared with previous studies [35,36] and
estimations and comparisons of positive and negative pre-
dictive values should thus be interpreted with caution.
Five children developed active TB during 12 month
follow-up. This highlights the importance of the provision
of preventive therapy to child contacts in this area.
Screening of child contacts is not routinely carried out in
the Orinoco Delta. Lack of staff expertise, the need for a
minimum of two appointments to complete screening,
transport costs and high healthcare worker workload have
been identified as barriers to contact screening in rural Af-
rica [37]. In rural South Africa, screening by five simple
questions was sufficient to exclude TB disease in child
contacts with a negative predictive value between 96% and
100% [38]. As community health workers are present in
many Warao villages, educating them to use symptom-
based approaches could potentially make screening of
child TB contacts feasible. Supervision of preventive treat-
ment by community health workers would be vital as poor
Table 2 Concordance rate of tuberculin skin test and QuantiFERON®-TB Gold In-Tube at inclusion
Tuberculin skin test, n (%) Total, n QuantiFERON®-TB Gold In-Tube, n (%) Total, n Kappa (95% CI)
Positive Negative Positive Negative Indeterminate*
Total 74 (45) 89 (55) 163 63 (42) 77 (51) 11 (7) 151 0.76 (0.46-1.06)
Active TB 6 (55) 5 (45) 11 7 (78) 1 (11) 1 (11) 9 0.39 (−0.19-0.97)
Chest-Xray in asymptomatic
children
TB sequelae 34 (56) 27 (44) 61 30 (52) 24 (41) 4 (7) 58 0.73 (0.54-0.91)
No features of TB 32 (37) 55 (63) 87 25 (31) 51 (62) 6 (7) 82 0.77 (0.62-0.92)
BCG vaccination status
BCG scar present 65 (46) 75 (54) 140 55 (42) 67 (51) 9 (7) 131 0.74 (0.62-0.86)
BCG scar absent 9 (39) 14 (61) 23 8 (40) 10 (50) 2 (10) 20 0.89 (0.68-1.09)
Age
0 - 4 years 4 (9) 41 (91) 45 2 (5) 32 (82) 5 (13) 39 0.79 (0.38-1.20)
5 - 15 years 70 (59) 48 (41) 118 61 (55) 45 (40) 6 (5) 112 0.69 (0.55-0.83)
*For calculation of kappa values, children with indeterminate QuantiFERON®-TB Gold In-Tube results were excluded.
Table 3 Factors predicting tuberculin skin test (TST) and QuantiFERON®-TB Gold In-Tube (QFT-GIT) positivity in Warao
Amerindian childhood contacts
Characteristics QFT-GIT positive vs. QFT-GIT negative TST positive vs. TST negative
Odds ratio (95% CI) Odds ratio (95% CI)
Age, years 0.99 (0.84-1.2) 1.4 (1.2-1.7)
Sex, male vs. female 0.6 (0.13-3.2) 3.7 (1.5-9.4)
Malnourished 4.6 (0.93-22.2) 0.92 (0.50-1.7)
BCG vaccination 0.51 (0.14-1.9) 0.68 (0.32-1.5)
Duration of exposure, ≥12 vs. <12 h/day 1.4 (0.35-5.65) 0.81 (0.34-1.9)
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Table 4 Demographics and test results for the five contacts who progressed to active tuberculosis during follow-up
Age, yr Sex BCG Malnourished* Duration
contact
(h/day)
TB
diagnosis
Time
point
diagnosis
QFT-GIT TST Chest X-ray
Inclusion TB diagnosis Inclusion TB
diagnosis
Inclusion TB diagnosis
Result IU/ml Result IU/ml Result mm Result mm
0 (6 mo) F Yes Yes <12 Probable 6 mo Nd Ind −23.123 Neg 0 Neg 2 Segmental
calcifications
Segmental calcifications, Ghon
focus with cavitation, lymph
node disease with tracheal
compression
1 M Yes Yes <12 Possible 6 mo Neg 0.024 Neg 0.012 Pos 10 Nd Segmental
parenchymal
destruction
paracardial region
right lung
Segmental parenchymal
destruction paracardial region
right lung, bilateral
parenchymal infiltrates lower
lobes
1 M Yes Yes ≥12 Probable 12 mo Neg 0.012 Neg 0.000 Neg 0 Neg 0 No abnormalities Alveolar consolidation right
upper lobe
6 M Yes No <12 Possible 6 mo Pos 3.045 Neg 0.133 Pos 10 Nd No abnormalities Lobar alveolar consolidation
right middle lobe
11 M Yes No <12 Probable 6 mo Pos 2.701 Pos 3.394 Pos 10 Nd Segmental
calcifications
Segmental calcifications, right
hilar lymph node enlargement,
alveolar consolidation left
upper lobe
yr = years, mo = months, h = hours, F = Female, M = Male, BCG = Bacille Calmette - Guérin, TB = Tuberculosis, QFT-GIT = QuantiFERON®-TB Gold In-Tube assay, TST = Tuberculin skin test, Nd = Not done,
Ind = Indeterminate, Pos = Positive, Neg = Negative.
*Reflects nutritional status upon inclusion.
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adherence to unsupervised chemotherapy has been re-
ported [39-41].
We did not observe a significant association of previous
BCG vaccination with either TST or QFT-GIT positivity.
Other studies performed in children from high burden
areas also did not report an association between BCG vac-
cination and TST positivity [42-46]. In contrast, two stud-
ies including children from low burden regions did
observe a significant association of BCG vaccination with
TST positivity and/or a low agreement between TST and
QFT-GIT results in BCG vaccinated children [36,47]. A
review by Dheda et al. assessing IGRA and TST utility in
high burden vs. low burden settings concluded that agree-
ment between IGRAs and the TST depends on the BCG
vaccination status of individuals in low burden countries,
whereas the concordance of IGRAs with TST is modest to
good and not clearly associated with BCG vaccination
status in high burden settings [6].
We observed both QFT-GIT conversions and reversions
among childhood contacts. Children with a recruitment
positive QFT-GIT result were more likely to have a differ-
ent result at 12 month follow-up than those with an
initially negative QFT-GIT. Other longitudinal studies in-
cluding childhood contacts in India and South Africa also
reported QFT-GIT conversions and reversions. In contrast
to our observations, these studies reported somewhat
higher rates of follow-up QFT-GIT results differing from
initial results in children who were initially QFT-GIT
negative compared with initially QFT-GIT positive chil-
dren [12,13]. The high number of children reverting from
IGRA positive to negative in our study could merely be
due to biological variations among IGRA positive individ-
uals. An alternative explanation is proposed by Hill and
colleagues, who suggest that IGRA responses are inher-
ently transient and require continued exposure to TB anti-
gens to maintain high frequencies. They argue that
reversions reflect the life cycle of M. tuberculosis, where
the mycobacterium enters a dormant state in which it
may not reliably secrete ESAT-6 and CFP-10 [48]. However,
our observation that the QFT-GIT response in IU/ml cor-
related significantly with CXR lesions suggestive of previous
TB, does not support the theory that QFT-GIT responses
decrease when clearing of TB infection occurs. Large com-
prehensive studies are needed to address this issue.
The percentage of Warao children that showed a differ-
ent QFT-GIT result at follow-up compared with their re-
cruitment result (33%) was higher than the overall rate of
changing results in studies from India (14%) [12] and
South Africa (28%) [13]. A Ugandan study showed a simi-
lar rate of changing results in five-year-old household con-
tacts (30%) at follow-up only three weeks after inclusion.
Table 5 Children without active TB who had radiographic
lesions possibly associated with tuberculosis sequelae
at inclusion
Radiographic characteristic* Number of children,
n (%)**
Calcification 46 (31)
Segmental 17 (11)
Lobar 2 (1)
Unilateral 3 (2)
Bilateral 24 (16)
Parenchymal destruction with fibrosis 5 (3)
Segmental 4 (3)
Lobar 0 (0)
Unilateral 0 (0)
Bilateral 1 (0)
Bronchiectasis 17 (11)
Segmental 2 (1)
Lobar 3 (2)
Unilateral 2 (1)
Bilateral 10 (7)
*The herementioned radiographic characteristics were defined as “consequences
of previous pulmonary tuberculosis” in the disease classification proposed by
Marais et al. [25].
**Percentages reflect the proportion of the total number of children without
active TB of whom a CXR was taken (n = 148).
Table 6 Results of multivariable logistic GEE regression analysis for the presence of TB sequelae on chest X-rays vs.
normal chest X-rays at inclusion*
TB sequelae on CXR Odds ratio 95% CI p-value
IFN-γ level, IU/ml** 1.05 1.0-1.1 0.049
TST induration diameter, mm 0.95 0.84-1.08 0.44
Age, years 1.3 1.0-1.6 0.029
Sex, male vs. female 1.8 1.0-3.0 0.034
Malnourished 0.39 0.15-1.0 0.055
BCG vaccination 2.7 1.2-6.4 0.020
Duration of exposure, ≥12 h/day vs. <12 h/day 0.90 0.55-1.5 0.69
*Individuals who had active TB, indeterminate QFT-GIT results and those in whom a CXR and/or QFT-GIT was not performed (n = 33) were excluded from this
analysis. A total of 55/130 remaining household contacts had radiological features of TB sequelae. Of these, 34 had calcifications as the lone abnormality.
**The level of IFN-γ (IU/ml) in the QFT TB antigen-stimulated plasma sample with that for the negative control subtracted.
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The authors conclude that the IGRA cannot be used alone
(without TST) to diagnose TB infection [49]. Indeed, the
observation that QFT-GIT results in our population show
a high variability over time complicates the potential use
of a single QFT-GIT test as a supportive test in the diag-
nosis of childhood TB. As long as it is not clear whether
conversions and reversions correlate with the degree of
clearing the TB infection or whether changes simply
reflect instability of IGRAs, single test results should be
interpreted with caution.
In a high number of children (41%) without active TB at
least one radiographic feature of possible TB sequelae was
observed on the CXR taken upon inclusion. In indigenous
TB contacts 0–19 years of age residing in the Brazilian
Amazon, a similar prevalence (33%) of radiographic fea-
tures possibly associated with TB sequelae was observed
and calcifications were also the most frequently observed
abnormality [50]. Both in the Brazilian as well as in our
study population reported TB rates are extraordinarily
high (>30 times higher than national estimates) [21,51].
Possibly, the high number of children demonstrating TB
sequelae on CXR is related to repeated TB exposure since
early childhood. However, the CXR lacks specificity for
detection of TB sequelae. Radiologic lesions suggestive of
inactive TB are also noticed in for example histoplasmosis,
a granulomatous disease caused by Histoplasma capsula-
tum that is endemic in Venezuela [52]. Further research
with a longer follow-up is needed to identify the specific
causes and prognosis of radiologic lesions.
We observed a significant association of the presence of
possible TB sequelae on CXR with age, sex and BCG vac-
cination status. Young children with less mature immune
responses may show less immune-mediated lung tissue
destruction than older children. In mice infected with M.
tuberculosis, BCG vaccination promoted pathological in-
flammation and lung lesions and this was mediated by
interleukin (IL)-17 [53]. According to a recently published
systematic review, BCG vaccination in humans produces
dramatically high levels of IL-17 [54]. We speculate that
repeated M. tuberculosis exposure in children living in
high burden areas leads to more immune-mediated lung
damage in those children that already developed an im-
mune response following BCG vaccination compared with
unvaccinated children.
A considerable number of children (n = 17, 11%) had
CXR findings indicating bronchiectasis. Our CXR defin-
ition of bronchiectasis was previously used in Alaska native
and Turkish children [27,28]. However, a CXR can suggest
but not confirm the presence of bronchiectasis [55]. CT of
the chest, especially high-resolution CT (HRCT), has be-
come the “gold standard” imaging modality for diagnosing
bronchiectasis [56]. (HR)CT equipment is unfortunately
not available in the hospitals and health posts in the Warao
communities. In indigenous children <15 years of age from
remote communities in Australia the prevalence rate of
HRCT-confirmed bronchiectasis was estimated to be 14.7/
1000 [57]. There are many other pathologies that can con-
tribute to bronchiectasis development apart from TB, eg,
pertussis, influenza, congenital malformations or foreign
body aspiration [58]. In Alaska native children and adults,
only 4% of patients with probable (defined by clinical and
CXR findings) and definite (diagnosed by bronchogram or
CT) bronchiectasis had a history of pulmonary TB. The
majority (74%) of patients included in the Alaskan study
was diagnosed with asthma [28]. In a recently published
cross-sectional survey a high prevalence of asthma symp-
toms (26%) in Warao Amerindian children aged between 2
and 10 years was observed [59]. The finding that most of
the children with X-ray findings suggestive of bronchiec-
tasis showed bilateral lesions (24/46, 52%) suggests that
other pathologies than TB have contributed to the bronch-
iectatic lesions. In Canadian patients with bronchiectasis,
previous TB was more often associated with unilateral than
with bilateral lesions (58% vs. 42% respectively) [60]. Stud-
ies including a control group of children without a TB con-
tact would be able to distinguish TB-related CXR lesions
from CXR findings related to other pathologies. However,
in a high burden setting where under-diagnosis and under-
registration of cases occur it is difficult to identify such a
comparison group.
A major limitation of our study was the limited number
of children with valid active follow-up data. The low pro-
portion of TST negative children in which repeat testing
was performed and the low proportion of children with a
valid QFT-GIT result at inclusion in which a follow-up
QFT-GIT was performed (respectively 67% and 38%) pre-
clude firm conclusions regarding TST conversions and
QFT-GIT conversions and reversions. Notably, we cannot
exclude the possibility that TST and QFT-GIT conversions
were related to ongoing transmission within the commu-
nity. Warao people are semi-nomadic and many migrate
each year temporarily from their villages for agricultural
purposes. Although passive follow-up was performed to
screen for additional active TB cases, we cannot exclude
the possibility that TB cases might have been missed.
Additionally, children with a positive TST result at base-
line did not receive a follow-up TST, and therefore we
could not explore the occurrence of TST reversions. Study
subjects with a BCG scar were reported as BCG vacci-
nated and vaccination cards were not examined. This may
have led to under-reporting of the number of children
with BCG vaccination since some BCG vaccinated
children may not develop a scar. However, household-
retained vaccination cards have also been identified as an
insufficient source of information for estimating vaccin-
ation coverage in other areas [61]. Finally, although we in-
cluded all child TB contacts of registered TB patients that
were encountered and willing to participate, we cannot
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rule out the possibility that child TB contacts were missed
due to under-registration of TB cases in the Orinoco Delta
Department of the Venezuelan National TB Control
Program.
Conclusions
In Warao Amerindian childhood TB contacts, TST results
were not significantly influenced by previous BCG vaccin-
ation and a substantial concordance between QFT-GIT
and TST was observed in both BCG vaccinated and un-
vaccinated children. Replacement of TST by the QFT-GIT
for estimation of LTBI prevalence rates is therefore not
recommended in this resource-constrained setting. The
QFT-GIT had a higher sensitivity than the TST in chil-
dren with active TB. However, the potential use of a single
QFT-GIT test as a supportive test in the diagnosis of
childhood TB is limited by the high variability in QFT-
GIT results over time. The relationship of radiographic
features of possible TB sequelae with immune mecha-
nisms and future progression to TB disease warrants
further investigation.
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